These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37929413)

  • 1. Deferasirox causing duodenal ulcer leading to upper gastrointestinal bleed and hemorrhagic shock in a child with beta-thalassemia major.
    Tresa A; Shankar GH; Sarangi BU; Walimbe A
    Indian J Pharmacol; 2023; 55(5):335-337. PubMed ID: 37929413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perforated Duodenal Ulcer Associated with Deferasirox in a Child with β-Thalassemia Major.
    Zahra A; Ragab A; Al-Abboh H; Ismaiel A; Adekile AD
    Hemoglobin; 2021 Sep; 45(5):335-337. PubMed ID: 34979847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perforated duodenal ulcer: a rare complication of deferasirox in children.
    Yadav SK; Gupta V; El Kohly A; Al Fadhli W
    Indian J Pharmacol; 2013; 45(3):293-4. PubMed ID: 23833377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance induction to deferasirox in a child with transfusion-dependent beta thalassemia.
    Pondrom M; Monpoux F; Rocher F; Gastaut N; Bailly-Piccini C; Poirée M
    Arch Pediatr; 2021 Jan; 28(1):101-103. PubMed ID: 33250331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced duodenal perforation in the paediatric patient with thalassemia major, an unreported side effect of iron- chelating agent: A case report.
    Shakir FTZ; Sultan R; Siddiqui R; Shah MZ; Javed A; Maryam N
    J Pak Med Assoc; 2022 Jul; 72(7):1441-1443. PubMed ID: 36156578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy And Tolerability Of Oral Iron Chelator, Deferasirox.
    Tahir A; Hussain SI; Khan HS; Khalil S; Haider SZ; Lodhi MA
    J Ayub Med Coll Abbottabad; 2021; 33(2):207-212. PubMed ID: 34137530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha.
    Panigrahi M; Swain TR; Jena RK; Panigrahi A; Debta N
    Indian J Pharmacol; 2020; 52(3):172-178. PubMed ID: 32873999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.
    Wei Z; Yang G; Huang Y; Peng P; Long L; Long Y; Huang X; Zhou X; Lai Y; Liu R
    Br J Haematol; 2020 Nov; 191(3):e81-e83. PubMed ID: 32945527
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
    Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
    Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
    Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and β-thalassemia.
    Oyedeji CI; Crawford RD; Shah N
    J Natl Med Assoc; 2021 Apr; 113(2):170-176. PubMed ID: 32892996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male.
    Fraser J; Brook R; He T; Lewis D
    BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32646935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.
    Lai YR; Cappellini MD; Aydinok Y; Porter J; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Liu R; Izquierdo M; Lasher J; Govindaraju S; Taher A
    Am J Hematol; 2022 Aug; 97(8):E281-E284. PubMed ID: 35560253
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J; Tolley K; Vieira J; Chandiwana D
    Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
    Cappellini MD; Cohen A; Piga A; Bejaoui M; Perrotta S; Agaoglu L; Aydinok Y; Kattamis A; Kilinc Y; Porter J; Capra M; Galanello R; Fattoum S; Drelichman G; Magnano C; Verissimo M; Athanassiou-Metaxa M; Giardina P; Kourakli-Symeonidis A; Janka-Schaub G; Coates T; Vermylen C; Olivieri N; Thuret I; Opitz H; Ressayre-Djaffer C; Marks P; Alberti D
    Blood; 2006 May; 107(9):3455-62. PubMed ID: 16352812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.